Premium
Prognostic molecular biomarkers for cutaneous malignant melanoma
Author(s) -
Tanaka Ryo,
Koyanagi Kazuo,
Narita Norihiko,
Kuo Christine,
Hoon Dave S.B.
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21969
Subject(s) - melanoma , medicine , epigenomics , lymph , molecular biomarkers , pathology , cancer research , oncology , dna methylation , biology , gene , gene expression , biochemistry
Abstract Molecular signatures of melanoma have propelled new approaches to early diagnosis, monitoring of treatment response, and targeted therapy. This review discusses messenger RNA (mRNA), genomic, and epigenomic melanoma biomarkers in blood and tissue specimens. The major focus is on tissue‐based molecular assays to upstage sentinel lymph nodes (SLNs), and blood‐based assays to detect melanoma progression by monitoring levels of circulating tumor cells (CTC) and circulating DNA. J. Surg. Oncol. 2011; 104:438–446. © 2011 Wiley‐Liss, Inc.